New Drug Sheds 28% Body Weight, Doctors Urge Caution

Eli Lilly has unveiled striking new data for retatrutide, an experimental drug for obesity that prompted patients to lose an average of 28 percent of their body weight. This represents a significant increase in potency compared to current GLP-1 medicines. Doctors, however, are advising caution, stressing the necessity of close medical oversight, particularly for individuals with a body mass index over 40.

Patients in the Phase 3 clinical trial lost an average of 70 pounds after 80 weeks at the highest dose, with continued weight loss observed beyond the typical plateau point for existing drugs. Experts warn that such substantial weight reduction without careful management of nutrition and exercise could endanger bone density and muscle mass. Eli Lilly plans to submit trial results to the FDA by the end of 2026, with potential approval in 2027.

While retatrutide offers promising enhanced results, the company noted that muscle mass loss is a normal part of weight loss interventions. Eli Lilly also reported that 11.3 percent of patients on the highest dose discontinued the drug due to side effects like nausea and diarrhea. The emergence of unregulated versions of retatrutide sold online for 'research' purposes before FDA approval is also a significant concern, potentially leading to self-experimentation without proper medical guidance.